The estimated Net Worth of Deborah Morosini is at least $473 Тысяча dollars as of 15 December 2021. Dr Morosini owns over 28,751 units of Prelude Therapeutics Inc stock worth over $145,975 and over the last 4 years he sold PRLD stock worth over $0. In addition, he makes $326,810 as Exec. VP & Chief of Clinical Affairs at Prelude Therapeutics Inc.
Sign up
Dr Morosini PRLD stock SEC Form 4 insiders trading
Dr has made over 6 trades of the Prelude Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 28,751 units of PRLD stock worth $336,387 on 15 December 2021.
The largest trade he's ever made was exercising 28,751 units of Prelude Therapeutics Inc stock on 15 December 2021 worth over $336,387. On average, Dr trades about 7,784 units every 55 days since 2020. As of 15 December 2021 he still owns at least 29,195 units of Prelude Therapeutics Inc stock.
You can see the complete history of Dr Morosini stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Deborah Morosini biography
Dr. Deborah Morosini is the Exec. VP & Chief of Clinical Affairs at Prelude Therapeutics Inc.
What is the salary of Dr Morosini?
As the Exec. VP & Chief of Clinical Affairs of Prelude Therapeutics Inc, the total compensation of Dr Morosini at Prelude Therapeutics Inc is $326,810. There are 1 executives at Prelude Therapeutics Inc getting paid more, with Dr. Krishna Vaddi D.V.M., Ph.D. having the highest compensation of $645,725.
How old is Dr Morosini?
Dr Morosini is 62, he's been the Exec. VP & Chief of Clinical Affairs of Prelude Therapeutics Inc since . There are no older and 4 younger executives at Prelude Therapeutics Inc.
What's Dr Morosini's mailing address?
Deborah's mailing address filed with the SEC is C/O PRELUDE THERAPEUTICS INCORPORATED, 200 POWDER MILL ROAD, WILMINGTON, DE, 19803.
Insiders trading at Prelude Therapeutics Inc
Over the last 5 years, insiders at Prelude Therapeutics Inc have traded over $822,895 worth of Prelude Therapeutics Inc stock and bought 5,875,215 units worth $87,687,261 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., David P Bonita и Advisors Llc Orbi Med Capit.... On average, Prelude Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of $608,735. The most recent stock trade was executed by Jane Huang on 4 July 2024, trading 9,375 units of PRLD stock currently worth $46,875.
What does Prelude Therapeutics Inc do?
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; and PRT-K4 that is in preclinical stage for solid tumors. Prelude Therapeutics Incorporated was incorporated in 2016 and is headquartered in Wilmington, Delaware.
What does Prelude Therapeutics Inc's logo look like?
Complete history of Dr Morosini stock trades at Prelude Therapeutics Inc
Prelude Therapeutics Inc executives and stock owners
Prelude Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Dr. Krishna Vaddi D.V.M., Ph.D.,
Founder, CEO & Director -
Dr. Deborah Morosini,
Exec. VP & Chief of Clinical Affairs -
Naveen Babbar,
Sr. VP of Translation Medicine -
Dr. Madhu Pudipeddi Ph.D.,
Sr. VP of Technical Operations -
Dr. Andrew P. Combs Ph.D.,
Exec. VP & Head of Chemistry -
Michele Porreca,
Chief People Officer -
Dr. Peggy A. Scherle Ph.D.,
Chief Scientific Officer -
Laurent Chardonnet,
Chief Financial Officer -
David P Bonita,
-
Martin Babler,
-
Bros. Advisors Lp667, L.P.B...,
-
Christopher Pierce,
EVP and Chief of Business Oper -
Deborah Morosini,
EVP, Chief of Clinical Affairs -
Advisors Llc Orbi Med Capit...,
-
Paul A Friedman,
-
Krishna Vaddi,
CEO -
David J Mauro,
Chief Medical Officer -
Brian Piper,
Chief Financial Officer -
Laurent Chardonnet,
Chief Financial Officer -
Jane Huang,
President, CMO -
Peggy Scherle,
Chief Scientific Officer -
Bryant David Lim,
CLO, Interim CFO, Corp Sec. -
Bros. Advisors Lp667, L.P.B...,
-
Victor Sandor,
-
Mardi Dier,